Dudon
Generic Name
Domperidone
Manufacturer
Square Pharmaceuticals Ltd.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| dudon 5 mg suspension | ৳ 30.00 | N/A |
Description
Overview of the medicine
Dudon 5 mg Suspension contains Domperidone, an antiemetic and prokinetic agent used to treat nausea and vomiting. It helps to move food faster through the stomach and intestines.
Uses & Indications
Dosage
Adults
10-20 mg (10-20 ml) three to four times daily, 15-30 minutes before meals and at bedtime. Maximum daily dose 80 mg.
Elderly
Similar to adult dose, but caution is advised due to potential for cardiac effects. Start with lower dose.
Children
0.25-0.5 mg/kg body weight, three to four times daily. (e.g., for a 20 kg child, 5 mg (5 ml) 3-4 times daily). Maximum 1.25 mg/kg daily, not exceeding 80 mg daily.
Renal_impairment
Severe renal impairment (creatinine clearance <30 mL/min): Frequency of dosing should be reduced to once or twice daily, depending on the severity of impairment.
How to Take
For oral administration. Shake well before use. It is recommended to take Dudon suspension 15-30 minutes before meals.
Mechanism of Action
Domperidone is a dopamine D2 and D3 receptor antagonist, primarily acting peripherally in the chemoreceptor trigger zone and on gastric smooth muscle. This action increases gastrointestinal motility and tone, facilitating gastric emptying and reducing esophageal reflux, and exerts antiemetic effects by blocking dopamine receptors in the CTZ.
Pharmacokinetics
Onset
Within 30-60 minutes.
Excretion
About 66% excreted in feces (mainly as metabolites) and 33% in urine (mainly as metabolites) over several days.
Half life
Approximately 7-9 hours in healthy volunteers; prolonged in severe renal impairment.
Absorption
Rapidly absorbed after oral administration, but bioavailability is low (15%) due to extensive first-pass metabolism in the gut wall and liver. Absorption is reduced by food.
Metabolism
Extensively metabolized in the liver by hydroxylation and N-dealkylation, primarily via CYP3A4.
Side Effects
Contraindications
- Hypersensitivity to Domperidone or any component of the formulation
- Patients with prolactin-releasing pituitary tumour (prolactinoma)
- Patients with moderate to severe hepatic impairment
- Patients with known existing prolongation of cardiac conduction intervals, particularly QTc
- Patients with significant electrolyte disturbances
- Concomitant use with potent CYP3A4 inhibitors (e.g., ketoconazole, erythromycin)
- Concomitant use with QT-prolonging drugs
Drug Interactions
Anticholinergics
May antagonize the prokinetic effect of Domperidone.
QT-prolonging drugs
Avoid concomitant use with drugs known to prolong the QT interval (e.g., Class IA and III antiarrhythmics, some antipsychotics, some antidepressants, some antibiotics like erythromycin, some antifungals like ketoconazole, some antihistamines).
Potent CYP3A4 inhibitors
Avoid concomitant use with potent CYP3A4 inhibitors (e.g., azole antifungals, macrolide antibiotics, HIV protease inhibitors, nefazodone), as they can increase Domperidone plasma levels and cardiac risk.
Antacids/Acid-suppressants
May reduce the bioavailability of Domperidone; take Domperidone before food and antacids after food.
Storage
Store below 30°C, protected from light and moisture. Do not freeze. Keep out of reach of children.
Overdose
Symptoms of overdose may include agitation, altered consciousness, convulsions, disorientation, somnolence, and extrapyramidal reactions. Treatment is symptomatic and supportive. Gastric lavage and activated charcoal may be considered if taken recently.
Pregnancy & Lactation
Pregnancy Category C. Should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Domperidone is excreted in breast milk; therefore, it is not recommended for nursing mothers unless the expected benefits outweigh the potential risks to the infant.
Side Effects
Contraindications
- Hypersensitivity to Domperidone or any component of the formulation
- Patients with prolactin-releasing pituitary tumour (prolactinoma)
- Patients with moderate to severe hepatic impairment
- Patients with known existing prolongation of cardiac conduction intervals, particularly QTc
- Patients with significant electrolyte disturbances
- Concomitant use with potent CYP3A4 inhibitors (e.g., ketoconazole, erythromycin)
- Concomitant use with QT-prolonging drugs
Drug Interactions
Anticholinergics
May antagonize the prokinetic effect of Domperidone.
QT-prolonging drugs
Avoid concomitant use with drugs known to prolong the QT interval (e.g., Class IA and III antiarrhythmics, some antipsychotics, some antidepressants, some antibiotics like erythromycin, some antifungals like ketoconazole, some antihistamines).
Potent CYP3A4 inhibitors
Avoid concomitant use with potent CYP3A4 inhibitors (e.g., azole antifungals, macrolide antibiotics, HIV protease inhibitors, nefazodone), as they can increase Domperidone plasma levels and cardiac risk.
Antacids/Acid-suppressants
May reduce the bioavailability of Domperidone; take Domperidone before food and antacids after food.
Storage
Store below 30°C, protected from light and moisture. Do not freeze. Keep out of reach of children.
Overdose
Symptoms of overdose may include agitation, altered consciousness, convulsions, disorientation, somnolence, and extrapyramidal reactions. Treatment is symptomatic and supportive. Gastric lavage and activated charcoal may be considered if taken recently.
Pregnancy & Lactation
Pregnancy Category C. Should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Domperidone is excreted in breast milk; therefore, it is not recommended for nursing mothers unless the expected benefits outweigh the potential risks to the infant.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
24 months
Availability
Available in pharmacies and hospitals nationwide
Approval Status
Approved by DGDA
Patent Status
Patent expired
WHO Essential Medicine
YesClinical Trials
Domperidone has been extensively studied in clinical trials demonstrating its efficacy in treating nausea, vomiting, and dyspepsia, with a well-established safety profile when used appropriately. Recent trials focus on cardiac safety, especially with revised dosing guidelines.
Lab Monitoring
- No routine lab monitoring required.
- ECG monitoring may be considered in patients at risk for cardiac events or those receiving high doses.
Doctor Notes
- Advise patients to use the lowest effective dose for the shortest possible duration.
- Screen patients for cardiac risk factors (e.g., pre-existing heart conditions, electrolyte imbalances) before prescribing.
- Warn about potential drug interactions with potent CYP3A4 inhibitors and QT-prolonging drugs.
- Not recommended for routine use in children unless specifically indicated by a pediatrician and under strict monitoring.
Patient Guidelines
- Take medicine before meals.
- Do not exceed the recommended dose or duration of treatment.
- Consult your doctor if symptoms persist or worsen.
- Inform your doctor about all other medications you are taking.
Missed Dose Advice
If you miss a dose, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and resume your regular dosing schedule. Do not take a double dose to make up for a missed one.
Driving Precautions
This medicine may cause dizziness, drowsiness, or visual disturbances. If you experience these effects, avoid driving or operating machinery.
Lifestyle Advice
- Avoid fatty foods and large meals that can exacerbate dyspepsia.
- Maintain a healthy diet and stay hydrated.
- Avoid smoking and excessive alcohol consumption if they worsen symptoms.
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine. Click a brand to search for detailed information.
Other Medicines in Dudon Brand
Other medicines available under the same brand name
